依达拉奉对脑出血患者神经肽Y和脑水肿的影响

摘要

目的 探讨依达拉奉对脑出血患者神经肽Y(Neuropeptider,NPY)和脑水肿的影响.方法 选择62例因脑出血在我院住院治疗的患者,采取随机数字表的方法选择32例患者为观察组,在常规治疗的基础上静脉点滴依达拉奉；余30例患者为对照组,只给予常规治疗.所有患者入院确诊后均由护士抽血检测NPY,并计算脑水肿体积及对患者神经功能缺损进行评分(NIHSS),第7天、14天复查并再次进行评分,对比分析其各项检测结果.结果 7d治疗后,观察组NIHSS评分较入院时明显降低(P＜0.01),NPY较同期对照组降低(P＜0.01)；14d治疗后,对照组NIHSS评分才有明显降低(P＜0.01),观察组较对照组降低更为明显(P＜0.05),NPY两组降低均较显著,且观察组降低更为明显(P＜0.01)；水肿体积观察组较对照组明显较低(P＜0.01).结论 依达拉奉可降低患者血浆NPY,阻断脑出血继发性脑水肿,改善患者神经功能状况.%Objective To analysis the effect of edaravone on neuropeptide Y (NPY) and cerebral edema in patients with cerebral hemorrhage. Methods Sixty-two patients with cerebral hemorrhage in our hospital were randomly divided into two groups. Patients in the study group (n=32) were treated with intravenous drip of edaravone based on routine treatment, while those in the control group (n=30) received routine treatment. The serum levels of NPY, the cerebral edema volume and the NIHSS score were investigated at admission, 7, 14 days after treatment. Results Seven days after treatment, the score of NIHSS was significantly lower than that at admission in the study group (P<0.01). The levels of NPY in the study group were significantly lower than those in the control group at the same time points (P<0.01); Fourteen days after treatment, the NIHSS scores started to decrease significantly (P<0.01), but the decrease was significantly less profound than that in the study group (P<0.05). The levels of NPY were significantly lowered in both the two groups, but the changes in the study group was more profound (P<0.01). The cerebral edema volume was significantly lower in the study group than the control group (P<0.01). Conclusion Edaravone can reduce the level of NPY, improve the neurological function and prevent secondary brain edema.